Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sulfamethoxazole/trimethoprim

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Sulfamethoxazole/trimethoprim. Displaying page 1 of 1.
    EudraCT Number: 2012-004424-38 Sponsor Protocol Number: SUTRICA Start Date*: 2013-01-29
    Sponsor Name:Department of Haematology, Aalborg University Hospital
    Full Title: A randomized, open-label phase III study of Clarithromycin, Sulfamethoxa-zole/Trimethoprim or observation in combination with standard therapy in patients with newly diagnosed multiple myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10021804 Infection bacterial LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005475-41 Sponsor Protocol Number: MLX Start Date*: 2014-11-05
    Sponsor Name:UZ Brussel
    Full Title: Sulfamethoxazole treatment of primary PREPL deficiency
    Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000219-25 Sponsor Protocol Number: MRSA Start Date*: 2013-07-18
    Sponsor Name:AOU Meyer
    Full Title: Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study.
    Medical condition: Patients affected by cystic fibrosis and who present an initial infection of MRSA.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005721-43 Sponsor Protocol Number: D4280C00002 Start Date*: 2012-05-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C...
    Medical condition: Complicated Urinary Tract Infections (cUTIs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) BG (Completed) DE (Completed) CZ (Completed) SK (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-005627-21 Sponsor Protocol Number: APHP211043 Start Date*: 2022-08-31
    Sponsor Name:APHP
    Full Title: 3-day intravenous antibiotic treatment versus 3-day intravenous followed by 7-day oral antibiotic treatment for acute pyelonephritis in children 1 month to 3 years old: a non-inferiority open rando...
    Medical condition: Acute pyelonephritis in children 1 month to 3 years old
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2011-005722-21 Sponsor Protocol Number: D4280C00004 Start Date*: 2012-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C...
    Medical condition: Complicated Urinary Tract Infections (cUTIs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021242-22 Sponsor Protocol Number: PHRN09-LB / DATIPO Start Date*: 2011-07-26
    Sponsor Name:CHRU de Tours
    Full Title: Etude multicentrique, de non infériorité, randomisée, ouverte, évaluant l’efficacité de deux Durées d’Antibiothérapie (6 semaines versus 12 semaines) dans le Traitement des Infections sur Prothèses...
    Medical condition: Infection sur prothèse ostéo-articulaire
    Disease: Version SOC Term Classification Code Term Level
    13.1 10061017 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005215-98 Sponsor Protocol Number: IUWP2005.01 Start Date*: 2007-03-12
    Sponsor Name:Sanquin Plasma Products
    Full Title: Treatment in patients with recurrent infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response.
    Medical condition: Established diagnosis of IgG subclass deficiency, and/or (selective) antipolysaccharide antibody deficiency.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021275 IgG subclass deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001466-11 Sponsor Protocol Number: SAVE Start Date*: 2020-04-15
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL
    Medical condition: Lower respiratory tract infection by Covid-19 at high risk for development of severe respiratory failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035738 Pneumonia viral NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004298-24 Sponsor Protocol Number: KCH-STR-INF Start Date*: 2008-08-13
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: A cluster randomised trial of different strategies of antibiotic use to reduce the incidence and consequences of chest infection in acute stroke patients with swallowing problems.
    Medical condition: Acute stroke patients with dysphagia and at high risk of aspiration as assessed by the bedside swallowing assessment. A policy to prevent pneumonias with prophylactic antibiotics is being investig...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10052081 Complication of acute stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005409-38 Sponsor Protocol Number: TriSulfa-FPI-1 Start Date*: 2013-04-19
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
    Full Title: Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis
    Medical condition: Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022096-54 Sponsor Protocol Number: Repha_1344 Start Date*: 2011-04-04
    Sponsor Name:Repha GmbH
    Full Title: Randomised, prospective, double-dummy double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus standard antibiotics in the treatment of acute uncomplicated cystitis
    Medical condition: Treatment of acute uncomplicated cystitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10011781 Cystitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004981-85 Sponsor Protocol Number: CD101.IV.3.08 Start Date*: 2020-04-06
    Sponsor Name:Cidara Therapeutics, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults...
    Medical condition: Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021241-44 Sponsor Protocol Number: PHRI06 – LB / PACHIU Start Date*: 2010-12-13
    Sponsor Name:CHRU de TOURS
    Full Title: Etude multicentrique, randomisée en groupes parallèles, évaluant l’efficacité et la tolérance d’un antibiocycle hebdomadaire dans la prévention des infections urinaires sur vessie neurologique.
    Medical condition: troubles de la vessie dû à une maladie neurologique
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000309-21 Sponsor Protocol Number: PREDICT_Trial_Amd_04 Start Date*: 2013-10-01
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Antibiotic Prophylaxis and Renal Damage In Congenital abnormalities of the kidney and urinary Tract
    Medical condition: Infants with vesicoureteral reflux grade III-V, started before the first symptomatic infection.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10047371 Vesicoureteral reflux LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) LT (Ongoing) ES (Ongoing) DE (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000338-20 Sponsor Protocol Number: MK-7655A-021 Start Date*: 2019-06-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Tha...
    Medical condition: Treatment of bacterial infections in pediatric populations
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10071097 Beta-lactam antibiotic resistance LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Ongoing) Outside EU/EEA ES (Restarted) BG (Ongoing) GR (Ongoing) NO (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001024-34 Sponsor Protocol Number: OraPAT-IE-GAMES Start Date*: 2021-12-15
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis.
    Medical condition: infective endocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10014666 Endocarditis bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000781-38 Sponsor Protocol Number: PHAO2011/LB/LIZ-BONE Start Date*: 2012-10-08
    Sponsor Name:Direction de la recherche clinique du centre hospitalier universitaire de Tours, Bretonneau
    Full Title: Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint...
    Medical condition: Hip prosthesis infected by gram-positive bacteria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10053021 Gram-positive bacterial infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000050-10 Sponsor Protocol Number: FORMaT001 Start Date*: 2023-01-02
    Sponsor Name:University of Queensland
    Full Title: Finding the Optimal Regimen for Mycobacterium abscessus Treatment
    Medical condition: Mycobacterium abscessus pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10064789 Mycobacterium abscessus infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001297-63 Sponsor Protocol Number: MLORI201 Start Date*: 2023-04-13
    Sponsor Name:Melinta Therapeutics, LLC
    Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 00:57:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA